EpimAb Biotherapeutics Inc.

岸迈生物科技有限公司

Clinical-stage biotechnology company developing bispecific antibody therapeutics, including T-cell engagers, for cancer and autoimmune diseases. Pipeline includes four clinical-stage candidates led by EMB-01 (EGFR/cMET) in Phase II for metastatic colorectal cancer, targeting markets including China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Chapter 18A biotech